2Mori T,Doi R,Toyoda E,et al. Regulation of the resistance to TRAIL - induced apoptosis as a new strategy for pancreatic cancer [ J ]. Surgery,2005,138 ( 1 ) : 71.
3Wang P,Zhang J,Jiang W,et al. Inhibition of RIP and c - FLIP enhances TRAIL- induced apoptosis in pancreatic cancer cells [ J ]. Cellular Signalling, 2007,19 ( 9 ) : 2237.
5Bratton SB, Cain K. Protein complexes activate distinct caspase cascades in death receptor and stress - induced apoptosis [J]. Exp cell Res,2000,256( 1 ) :27.
6Barczyk K,Kreuter M,Pryjma J,et al. Serum cytochrome c indicates in vivo apoptosls and can serve as a prognostic marker during cancer therapy [ J ]. Int J Cancer,2005,116 (2) : 167.
7HU WH,Johndon H,Shu HB. Tumor necrosis factor - related apoptosis - inducing ligand receptors signal NF - kappa B and JNK activation and apoptosis through distinct pathway [ J ]. J Biol Chem, 1999,274(43 ) :30603.
8Irmler M,Thome M,Hahne M,et al. Inhibition of death receptor signals by cellular FLIP[ J ]. Nature, 1997,388 (10) :190.
9Vignati S, Codegoni A, Polato F, et al. Trail activity in human ovarian cancer cells: potentiation of the action of cytotoxic drugs [ J ]. Cancer,2002,38 ( 1 ) : 177.
10Xiao CW,Yan X,Li Y,et al. Resistance of human ovarian cancer cells to tumor necrosis factor alpha is a consequence of nu- clear factor kappa B - mediated induction of Fas - associated death domain - like interleukin - 1 betaconverting enzyme - like inhibitory protein[ J ]. Endocrinology ,2003,44 ( 3 ) :623.
二级参考文献62
1Yang L, Cao Z, Yan H , et al. Coexistence of high levels of apoptotic signaling and inhibitor of apoptosis proteins in human tumor cells : implication for cancer specific therapy [ J ] . Cancer Res, 2003, 63(20) : 6815 - 6824.
2Ramp U, Krieg T, Caliskan E, et al. XIAP expression is an independent prognostic marker in clear-cell renal carcinomas [J]. Hum Pathol, 2004, 35(8) : 1022 - 1028.
3Peter I., Natalie R , Katsuyukl T, et al. Suppression of apoptosis in mammalian cells by NAPI and a related family of IAP genes[J]. Nature, 1996, 379( 15) : 349 - 353.
4Gruslin A, Qiu Q, Tsang BK. Influence of maternal smoking on trophoblast apoptosis throughout development : possible involvement of XIAP regulation [ J ]. Biol Reprod, 2001 , 65(4) : 1164 - 1169.
5Li J, Feng Q, Kim JM, et al.Human ovarian cancer and cisplatin resistance : possible role of inhibitor of apoptosis proteins [ J ].Endocrinology,2001,142(1) : 370 - 380.
6Ferreira CG, van der Valk P, Span SW, et al. Expression of X- linked inhibitor of apoptosis as a novel prognostic marker in radically resected non-small cell lung cancer patients [ J ].Clin Cancer Res, 2001 , 7 (8) : 2468 - 2674.
7Hofmann HS, Simm A, Hammer A, et al. Expression of inhibitor of apoptosis proteins (IAP) in non-small cell human lung cancer [ J ]. J Cancer Res Clin Oncol, 2002, 128(10) : 554 - 560.
8Lee YK, Bone ND, Strege AK, et al. VEGF Receptor phosphorylation status and apoptosis is modulated by a green tea component , epigallocatechin- 3 -gallate ( EGCG ) in B cell chronic lymphocytic leukemia [ J ]. Blood, 2004, 104 ( 3 ) : 788 - 794.
9Wiley S R,Schooley K,Smolak P J,et al.Identification and characterization of a new membe of the TNF family that induces apoptosis.Immunity,1995,3(6):673-682.
10Buchsbaum D J,Zhou T,Lobuglio A F,et al.TRAIL receptor-targeted therapy.Future Oncol,2006,2(4):493-508.
1Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity, 1995,3 (6) : 673-682.
2Yoldas B, Ozer C, Ozen O, et al. Clinical significance of TRAIL and TRAIL receptors in patients with head and neck cancer. Head Neck, 2011,33(9) : 1278-1284.
3Shivapurkar N, Toyooka S, Toyooka KO, et al. Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types. Int J Cancer, 2004,109 (5) : 786-792.
4Trarbach T, Moehler M, Heinemann V, et al. Phase 11 trial of mapatumumab, a fully human agonistie monoelonal antibodythat targets and activates the tumour necrosis factor apoptosis- inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer. Br J Cancer, 2010,102(3) :506-512.
5Jiang M, Liu Z, Xiang Y, et al. Synergistic antitumor effect of AAV-mediated TRAIL expression combined with cisplatin on head and neck squamous cell carcinoma. BMC Cancer, 2011,11:54.
6Lashinger LM, Zhu K, Williams SA, et al. Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells. Cancer Res, 2005,65 ( 11 ) : 4902-4908.
7Nikrad M, Johnson T, Puthalalath H, et al. The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim. Mol Cancer Ther, 2005,4(3) :443-449.
8Koschny R, Holland H, Sykora J, et al. Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Clin Cancer Res, 2007,13 ( 11 ) : 3403-3412.
9Shim SH, Lee CT, Hun Hah J, et al. Conditionally replicating adenovirus improves gene replication efficiency and anticancer effect of El-deleted adenovirus carrying TRAIL in head and neck aquamous cell carcinoma. Cancer Sci, 2010,101 (2) :482-487.
10Elord HA, Fan S, Muller S, et al. Analysis of death receptor 5 and caspase-8 expression in primary and metastatic head and neck squamous cell carcinoma and their prognostic impact. PLoS One, 2010,5(8) :e12178.
